Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Intangibles (2021)

Kiniksa Pharmaceuticals International filings provide 1 years of Change in Intangibles readings, the most recent being $20.0 million for Q1 2021.

On a quarterly basis, Change in Intangibles changed N/A to $20.0 million in Q1 2021 year-over-year; TTM through Dec 2021 was $20.0 million, a N/A change, with the full-year FY2021 number at $20.0 million, changed N/A from a year prior.
Change in Intangibles hit $20.0 million in Q1 2021 for Kiniksa Pharmaceuticals International.
In the past five years, Change in Intangibles ranged from a high of $20.0 million in Q1 2021 to a low of $20.0 million in Q1 2021.